Arcus Biosciences Key Fundamental And Technical Indicators

Stocks . USA . 
Stock . Arcus Biosciences
RCUS Stock  USD 25.36  0.58  2.34%   
Arcus Biosciences' ratios page distills the financial statements into the key efficiency, leverage, and profitability metrics. Arcus Biosciences trades at a price-to-earnings ratio of 27.69. The current ratio is 6.22, showing the ability to cover short-term obligations. As measured in the latest period, Arcus Biosciences posts the 14-period RSI reading of 55, consistent with balanced price action. This neutral positioning leaves Arcus Biosciences equally poised for a directional breakout in either direction.
Momentum
OversoldOverbought
55 · Neutral
As of the 9th of May, Arcus Biosciences trades around 25.36 per share. Indicator dispersion currently includes mean deviation of 3.21, and Risk Adjusted Performance of 0.0687. The evaluation incorporates historical dispersion and relative strength measures. Normalized comparisons highlight positioning versus competitors.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
Arcus Biosciences' quarterly and annual disclosures provide the raw data needed to benchmark against sector peers. Key fundamentals forming a complete picture of value appear below: Understanding Arcus Biosciences' revenue composition, cost structure, and debt maturity is central to valuation. Core metrics are listed below:
 Gross Profit
-287 million
 Profit Margin
-150.0%
 Market Capitalization
3.12 billion
 Enterprise Value Revenue
9.73
 Revenue
236 million
Fundamental screening for Arcus Biosciences draws on one hundred twenty available fundamental signals tracked across multiple periods. The present fundamental picture for Arcus Biosciences gains context when measured against multi-year trends spanning 2010 and 2026. In the latest reported period, Market Cap is holding steady around $2.53 billion. Also, Enterprise Value is holding steady around $2.5 billion. Cross-market screening tools are available via Equity Screeners for extended research. Peer comparisons and sector-level screening add context beyond individual analysis.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Balance Sheet Accounts

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets$865.86 million$1.14 billion552.7 M
Moderate Growth
Other Current Liabilities$205.8 million$196 million44.7 M
Moderate Growth
Total Current Liabilities$129.76 million$231 million79 M
Consistent Growth
Total Stockholder Equity$465.4 million$631 million311.4 M
Moderate Growth
Other Liabilities$456.44 million$434.7 million160.1 M
Consistent Growth
Property Plant And Equipment Net$52.17 million$40 million34 M
Moderate Growth
Accounts Payable$44.1 million$42 million12.1 M
Moderate Growth
Cash$145.08 million$222 million109.1 M
Moderate Growth
Non Current Assets Total$134.82 million$132 million83.6 M
Moderate Growth
Non Current Assets Other$96.6 million$92 million23.4 M
Moderate Growth
Other Assets$8.5 million$16.1 million6.4 M
Moderate Growth
Cash And Short Term Investments$624.18 million$981 million405.4 M
Consistent Growth
Net Receivables$10.45 million$11 million51.9 M
High Variability
Common Stock Shares Outstanding65.98 million107.4 million47.8 M
Consistent Growth
Short Term Investments$479.1 million$759 million296.3 M
Consistent Growth
Liabilities And Stockholders Equity$865.86 million$1.14 billion552.7 M
Moderate Growth
Non Current Liabilities Total$270.7 million$277 million162.3 M
Moderate Growth
Capital Surplus$1.35 billion$1.29 billion509.9 M
Consistent Growth
Other Current Assets$27.3 million$26 million8.3 M
Consistent Growth
Total Liabilities$400.46 million$508 million241.3 M
Moderate Growth
Property, Plant and Equipment (Gross)$57.67 million$90 million37.3 M
Moderate Growth
Preferred Stock Total Equity$190.11 million$260.13 million182.1 M
Moderate Growth
Total Current Assets$731.04 million$1.01 billion469.1 M
Moderate Growth
Non Current Liabilities Other$144.1 million$135 million85.6 M
High Variability
Common Stock$2.22 billion$2.12 billion498.3 M
Moderate Growth
Property Plant Equipment$163.01 million$155.25 million50.5 M
Moderate Growth
Current Deferred Revenue$61.46 million$35 million35.3 M
Moderate Growth
Common Stock Total Equity$5,280$8,0504.7 K
Consistent Growth
Deferred Long Term Liabilities$2.56 million$2.7 million4.1 M
High Variability
Net Invested Capital$522.92 million$730 million345.8 M
Moderate Growth
Net Working Capital$656.7 million$776 million422.3 M
Moderate Growth
Short Term Debt$7.24 million$13.8 million5.6 M
Moderate Growth
Capital Stock$2.22 billion$2.12 billion498.3 M
Moderate Growth
Short and Long Term Debt Total$78.85 million$99 million40.6 M
Moderate Growth
Capital Lease Obligations$22.82 million$13 million20.4 M
High Variability
Long Term Debt$80.85 million$99 million52.9 M
High Variability

Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income$34.65 million$33 million10.7 M
Moderate Growth
Interest Income$43.05 million$41 million12.2 M
Moderate Growth
Depreciation And Amortization$12.07 million$11.5 million4.3 M
Consistent Growth
Selling General Administrative$67.8 million$110 million41.6 M
Consistent Growth
Other Operating Expenses$664.65 million$633 million212.6 M
Consistent Growth
Research Development$549.15 million$523 million167 M
Consistent Growth
Cost Of Revenue$10.93 million$11.5 million40.7 M
High Variability
Total Operating Expenses$654.15 million$623 million211.4 M
Consistent Growth
Total Other Income Expense Net$34.65 million$33 million10.6 M
Moderate Growth
Reconciled Depreciation$6.34 million$11.5 million4.6 M
Moderate Growth
Non Operating Income Net Other$339,435$357,3003.2 M
Consistent Decline
Selling And Marketing Expenses$13.6 million$15.3 million16.7 M
Stable

Cash Flow Statement Items

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation$40.09 million$60 million23.8 M
Consistent Growth
Begin Period Cash Flow$126.87 million$153 million91.9 M
Moderate Growth
Other Cashflows From Financing Activities$512.4 million$488 million97.9 M
High Variability
Depreciation$6.73 million$11.5 million4.5 M
Moderate Growth
Capital Expenditures$1.9 million$2 million6.4 M
High Variability
Change To Operating Activities$27.77 million$26.45 million9.6 M
Consistent Growth
Total Cash From Financing Activities$512.4 million$488 million161.6 M
Moderate Growth
End Period Cash Flow$146.45 million$225 million109.9 M
Moderate Growth
Change To Netincome$91.77 million$87.4 million29.3 M
Consistent Growth
Issuance Of Capital Stock$450.45 million$429 million173.4 M
High Variability
Dividends Paid$4 million$4.5 million4.9 M
Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.84x10.36x148
Consistent Decline
PTB Ratio2.364.063.3562
Moderate Decline
Days Sales Outstanding30.2431.8367.457
High Variability
Book Value Per Share5.55.885.7985
High Variability
Stock Based Compensation To Revenue0.41x0.24x0.3815
High Variability
Capex To Depreciation$0.19$0.22.0612
Moderate Decline
PB Ratio2.36x4.06x3.3562
Moderate Decline
EV To Sales9.37x9.86x114
Consistent Decline
Payables Turnover0.270.310.3339
Stable
Sales General And Administrative To Revenue0.42x0.45x2.9413
Consistent Decline
Research And Ddevelopement To Revenue2.01x2.12x17.2095
Consistent Decline
Capex To Revenue0.01x0.01x1.8941
Consistent Decline
Cash Per Share7.019.136.9897
Moderate Growth
Days Payables Outstanding859.34966.751.1 K
Stable
Current Ratio4.144.3611.7754
Consistent Decline
Tangible Book Value Per Share5.55.885.7985
High Variability
Receivables Turnover11.2711.8744.2197
Moderate Decline
Shareholders Equity Per Share5.55.885.7985
High Variability
Debt To Equity0.09x0.16x0.0657
Moderate Growth
Capex Per Share0.020.020.1463
High Variability
Graham Net Net$5.16$4.44.3421
High Variability
Revenue Per Share1.422.31.0418
Moderate Growth
Interest-Bearing Debt Per Share1.0310.5883
High Variability
Debt To Assets0.05x0.09x0.0364
Moderate Growth
Graham Number$11.56$1314.1905
Stable
Operating Cycle$30.24$31.8367.457
High Variability
Price Book Value Ratio2.36x4.06x3.3562
Moderate Decline
Days Of Payables Outstanding859.34966.751.1 K
Stable
Ebt Per Ebit$1.05$0.910.967
Stable
Company Equity Multiplier1.34x1.81x1.4548
Moderate Growth
Long Term Debt To Capitalization0.09x0.14x0.0926
Moderate Variation
Total Debt To Capitalization0.08x0.14x0.0595
Moderate Growth
Debt-to-Equity Ratio0.090.160.0657
Moderate Growth
Quick Ratio4.144.3611.7754
Consistent Decline
Net Income Per EBT$0.8$0.920.9604
Stable
Cash Ratio0.910.966.0784
Consistent Decline
Days Of Sales Outstanding30.2431.8367.457
High Variability
Free Cash Flow Operating Cash Flow Ratio1.1911.1717
Moderate Decline
Price To Book Ratio2.36x4.06x3.3562
Moderate Decline
Fixed Asset Turnover6.486.171.8075
Consistent Growth
Debt Ratio0.050.090.0364
Moderate Growth
Price Sales Ratio9.84x10.36x148
Consistent Decline
Asset Turnover0.230.220.0804
Consistent Growth
Gross Profit Margin77.00%86.00%0.9425
Stable
Price Fair Value2.36x4.06x3.3562
Moderate Decline

Valuation Indicators

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap$2.65 billion$2.53 billion1.3 B
Consistent Growth
Enterprise Value$2.63 billion$2.5 billion1.2 B
Consistent Growth

Core Fundamental Drivers

Return On Equity TTM Driver Correlations

The account-level correlation structure for Return On Equity TTM at Arcus Biosciences surfaces the strongest financial relationships. Inverse correlations between certain accounts may indicate diversification within Arcus Biosciences' operations.
Click cells to compare fundamentals
Competition

Arcus Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

$-5.99 million
Accumulated Other Comprehensive Income stood at $-6.3 million as of December 31, 2025.

Arcus Biosciences Fundamental Drivers Relationships

ROE stood at -0.59 as of December 31, 2025. Related reported metric: Return On Asset TTM at -33.00% as of December 31, 2025.

Main Technical Indicators as of May 9, 2026

Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators
Risk Adjusted Performance0.0687
Market Risk Adjusted Performance-0.54
Mean Deviation3.21
Semi Deviation3.54
Downside Deviation3.81
Coefficient Of Variation1582.71
Standard Deviation4.31
Variance18.59
Information Ratio0.0614
Jensen Alpha0.2614
Total Risk Alpha0.272
Sortino Ratio0.0694
Treynor Ratio-0.55
Maximum Drawdown24.57
Value At Risk-6.23
Potential Upside7.11
Downside Variance14.51
Semi Variance12.53
Expected Short fall-3.37
Skewness0.975
Kurtosis2.69

Daily Market Strength Indicators

Market strength indicators for Arcus Biosciences quantify how the stock responds to shifts in volume and sentiment. These indicators capture shifts in momentum that may precede significant price moves in Arcus Biosciences. The Market Facilitation Index measures how efficiently price moves relative to volume — rising MFI with rising volume signals strong trend participation. Monitoring these indicators for Arcus Biosciences through complete market cycles reveals recurring patterns.
Accumulation Distribution51587.7
Daily Balance Of Power0.4234
Rate Of Daily Change1.02
Day Median Price25.02
Day Typical Price25.13
Price Action Indicator0.63
Period Momentum Indicator0.58
Relative Strength Index55.65

Basic Forecasting Models

MACD analysis of Arcus tracks the relationship between two exponential moving averages of Arcus Biosciences' price. Many Arcus Biosciences' traders use Fibonacci levels to set entry and exit targets based on prior price swings. Average True Range measures the typical daily price swing for Arcus, accounting for gaps. The frequency and magnitude of gaps reveal how much new information is being priced into Arcus outside regular hours.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

Arcus Biosciences Related Equities

Investors studying Arcus Biosciences often look at related stocks within the Health Care space to gauge pricing and results. Return on equity across these peers shows how well each firm turns capital into profit. A stock that beats its peers on many metrics often deserves a closer look from value-focused investors. Tracking Arcus Biosciences' results against these peers over time helps spot rising trends early.
 Risk & Return  Correlation

Return On Equity TTM Peer Comparison

The Return On Equity TTM peer comparison for Arcus Biosciences contextualizes its performance relative to the competitive set. This peer-based view of Return On Equity TTM evaluates Arcus Biosciences relative pricing within the sector. A sustained gap between Arcus Biosciences' Return On Equity TTM and peer averages deserves closer fundamental investigation. The resulting analysis reveals whether Arcus Biosciences stands out within its competitive group.
Arcus Biosciences is currently under evaluation in return on equity ttm relative to competitors.

Important Fundamentals

Return On Equity TTM-0.7
Return On Asset TTM-0.23
Profit Margin TTM-1.56
Operating Margin TTM-7.88
Current Valuation2.4 B
Shares Outstanding125.77 M
Shares Owned By Insiders29.13 %
Shares Owned By Institutions74.86 %
Number Of Shares Shorted11.07 M
Price To Earnings TTM27.69 X
Price To Book TTM5.19 X
Price To Sales TTM13.21 X
Revenue TTM247 M
Gross Profit TTM-287 M
EBITDA TTM-335 M
Net Income TTM-353 M
Cash And Equivalents TTM1.05 B
Cash Per Share TTM14.48 X
Total Debt TTM99 M
Debt To Equity TTM0.17 %
Current Ratio TTM6.22 X
Book Value Per Share TTM5.04 X
Cash Flow From Operations TTM-482 M
Short Ratio TTM10.28 X
Earnings Per Share-3.17 X
Target Price34.3
Number Of Employees601
Trailing Beta0.87
Market Capitalization TTM3.12 B
Total Asset TTM1.14 B
Retained Earnings TTM-1.49 B
Working Capital TTM776 M
Net Asset1.14 B

Financial Metrics, Fundamentals & Methodology

Arcus Biosciences's core fundamentals cover profitability, capital efficiency, and funding structure. The mix of equity and liabilities defines Arcus Biosciences's aggregate capital risk. For the latest reporting period, Arcus Biosciences reports revenue of 247 million, EPS loss of 3.17, negative operating margin of 7.88%.

Arcus Biosciences figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Professional analyst research is incorporated when coverage is available. Financial statement fields are presented under issuer-reported GAAP or IFRS accounting conventions.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.